Per‐ and Polyfluoroalkyl Substance Exposure, Gestational Weight Gain, and Postpartum Weight Changes in Project Viva

Mitro, Susanna D.; Sagiv, Sharon K.; Rifas‐Shiman, Sheryl L.; Calafat, Antònia M.; Fleisch, Abby F.; Jaacks, Lindsay M.; Williams, Paige L.; Oken, Emily; James‐Todd, Tamarra

doi:10.1002/oby.22933

Cited by 18 publications

(26 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple studies reported that certain PFAS measured in maternal blood during pregnancy were associated with greater gestational weight gain [551][552][553][554][555]. Gestational weight gain is associated with greater infant adiposity at birth [556].…”

Section: Human Studiesmentioning

confidence: 99%

Obesity II: Establishing causal links between chemical exposures and obesity

Heindel¹,

Howard²,

Agay-Shay³

et al. 2022

Biochemical Pharmacology

100

View full text Add to dashboard Cite

Section: Human Studiesmentioning

confidence: 99%

Obesity II: Establishing causal links between chemical exposures and obesity

Heindel¹,

Howard²,

Agay-Shay³

et al. 2022

Biochemical Pharmacology

100

View full text Add to dashboard Cite

“…For example, prenatal PFAS exposure has been linked to excessive gestational weight gain ( Ashley-Martin et al. 2016 ; Mitro et al. 2020 ), preterm birth ( Meng et al.…”

Section: Introductionmentioning

confidence: 99%

“…Exposure to PFAS has been linked to a wide array of adverse health outcomes, including reproductive outcomes (Blake and Fenton 2020). For example, prenatal PFAS exposure has been linked to excessive gestational weight gain (Ashley-Martin et al 2016;Mitro et al 2020), preterm birth (Meng et al 2018;Waterfield et al 2020), and preeclampsia (Savitz et al 2012;Stein et al 2009).…”

Section: Introductionmentioning

confidence: 99%

Maternal Levels of Perfluoroalkyl Substances (PFAS) during Early Pregnancy in Relation to Preeclampsia Subtypes and Biomarkers of Preeclampsia Risk

Bommarito

Ferguson

Meeker

et al. 2021

Environ Health Perspect

View full text Add to dashboard Cite

Background: Prenatal exposure to perfluoroalkyl substances (PFAS) has been previously associated with preeclampsia, although findings are mixed with respect to the direction and magnitude of effect. To our knowledge, no studies have examined associations between PFAS and preeclampsia subtypes, which may have distinct etiologies. Objective: We examined associations between PFAS, any preeclampsia diagnosis, and early- and late-onset preeclampsia. In addition, we estimated associations between PFAS and the angiogenic biomarkers soluble fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PlGF), which provide an estimate of pro- and anti-angiogenic activity within the placenta. Methods: This case–control study ( cases, controls) was sampled from the LIFECODES birth cohort. Nine legacy PFAS were quantified in maternal plasma from early pregnancy ( 10 wk) and angiogenic biomarkers were quantified in maternal plasma from four study visits ( 10, 18, 26, and 35 wk). Logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) of the association between an interquartile range (IQR)-increase in PFAS and preeclampsia outcomes. Linear regression was used to estimate associations between an IQR-increase in PFAS and concentrations of angiogenic biomarkers. Results: Both perfluorodecanoic acid ( 1.64, 95% CI: 1.08, 2.47) and perfluorooctanesulfonic acid ( 1.60, 95% CI: 1.06, 2.43) were associated with higher odds of late-onset preeclampsia. Associations tended to be below the null for early-onset preeclampsia, although findings were imprecise. Few associations were noted between PFAS and angiogenic biomarkers. Discussion: Maternal PFAS concentrations were associated with higher odds of late-onset preeclampsia. Heterogeneity of preeclampsia should be considered in future studies because populations may have different distributions of disease subtypes. https://doi.org/10.1289/EHP9091

show abstract

“…Similarly, EtFOSAA was linked to prevalent microvascular disease in a non-pregnant U.S. population in the Diabetes Prevention Program Outcomes Study [17]. In prior work in this cohort, we also found that EtFOSAA is associated with higher gestational weight gain [47]. PFAS may be causing increased adiposity by activating PPAR [ 21 22], which is expressed in adipose tissue and regulates adipocyte differentiation as well as fatty acid storage [48].…”

Section: Discussionmentioning

confidence: 61%

Pregnancy Per- and Polyfluoroalkyl Substance Concentrations and Postpartum Health in Project Viva: A Prospective Cohort

Mitro

Sagiv

Fleisch

et al. 2020

The Journal of Clinical Endocrinology &Amp; Metabolism

Self Cite

View full text Add to dashboard Cite

Abstract Context Per- and polyfluoroalkyl substances (PFAS) are environmental chemicals linked to weight gain and type 2 diabetes. Objective We examined the extent to which PFAS plasma concentrations during pregnancy were associated with postpartum anthropometry and biomarkers. Design, Patients, Measures We studied women recruited between 1999-2002 in the Project Viva prospective cohort with pregnancy plasma concentrations of PFAS, including perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2-(N-ethyl-perfluorooctane sulfonamide) acetic acid (EtFOSAA). Three-year postpartum anthropometry measurements were available from 786-801 women, blood pressure from 761 women, and blood biomarkers from 450-454 women. We used multivariable regression to evaluate the association of log2-transformed PFAS with postpartum anthropometry, blood pressure, and blood biomarkers (leptin, adiponectin, sex hormone binding globulin [SHBG], hemoglobin A1c [HbA1c], interleukin-6 [IL-6], C-reactive protein [CRP]), adjusting for age, pre-pregnancy BMI, marital status, race/ethnicity, education, income, smoking, parity, and breastfeeding history. Results Pregnancy concentrations of certain PFAS were associated with greater adiposity (e.g., 0.4 cm [95%CI: -0.1, 0.9] greater waist circumference per doubling in EtFOSAA; 0.2 cm [95%CI: -0.1, 0.5] greater mid-upper arm circumference per doubling in PFOA; 1.2 mm [95%CI: 0.1, 2.2] thicker sum of subscapular and triceps skinfolds per doubling in PFOS) and higher systolic blood pressure (e.g., 1.2 mm Hg [95%CI: 0.3, 2.2] per doubling in PFOS) at three years postpartum. Higher EtFOSAA concentrations were also associated with 10.8% higher IL-6 (95%CI: 3.3, 18.9) and 6.1% lower SHBG (95%CI: 0.7, 11.2) per doubling. Conclusions Pregnancy concentrations of EtFOSAA, PFOS, and PFOA were associated with adverse postpartum cardiometabolic markers.

show abstract

Per‐ and Polyfluoroalkyl Substance Exposure, Gestational Weight Gain, and Postpartum Weight Changes in Project Viva

Cited by 18 publications

References 48 publications

Obesity II: Establishing causal links between chemical exposures and obesity

Obesity II: Establishing causal links between chemical exposures and obesity

Maternal Levels of Perfluoroalkyl Substances (PFAS) during Early Pregnancy in Relation to Preeclampsia Subtypes and Biomarkers of Preeclampsia Risk

Pregnancy Per- and Polyfluoroalkyl Substance Concentrations and Postpartum Health in Project Viva: A Prospective Cohort

Contact Info

Product

Resources

About